As per the findings of the Phase 1/2 randomized clinical trial, published in The Lancet Infectious Diseases journal, the vaccine candidate could induce an antibody response in participants within 28 days of the first immunization, by giving two doses 14 days apart. The researchers from the Jiangsu Provincial Center for Disease Control and Prevention in China, also found the optimum dose to generate the highest antibody responses while taking account of side effects and production capacity.
While the average levels of neutralizing antibodies induced by CoronaVaccine was lower than levels seen in people who have previously had COVID-19, the scientists still believe the formulation could provide sufficient protection against the virus based on their experience with other vaccines and data from animal model studies. Since the study only included healthy adults aged 18 to 59 years, the researchers said further studies will be needed to test the vaccine candidate in other age groups, as well as in people with pre-existing medical conditions.
In the current study, the scientists reported the results of the Phase 1/2 clinical trial which included participants aged 18 to 59 years, and only people who did not have any history of infection with COVID-19.
Cipla launches 'Covi-G' for Covid-19: stock rise
Iranian companies has started COVID 19 vaccine human trials
